| Luris Sanchez, MD | |
|
828 Creswell Ln, Opelousas, LA 70570-5882 | |
| (337) 942-8088 | |
| (337) 942-8018 |
| Full Name | Luris Sanchez |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 30 Years |
| Location | 828 Creswell Ln, Opelousas, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205832235 | NPI | - | NPPES |
| 1999296 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 10955R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Landry Homecare | Opelousas, LA | Home health agency |
| Opelousas General Health System | Opelousas, LA | Hospital |
| St Martin Hospital | Breaux bridge, LA | Hospital |
| Entity Name | Luris Sanchez Md Apmc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316989049 PECOS PAC ID: 0648282467 Enrollment ID: O20060619000130 |
News Archive
In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).
Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.
Antihistamines and nasal steroids offer good short-term options for people with mild allergy, but allergy immunotherapy, better known as "allergy shots," is a preferred method for achieving long term remission of more bothersome allergy symptoms. Allergists mark the 100th anniversary of immunotherapy and present the latest advances at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting in Phoenix, Nov. 11-16.
Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.
› Verified 3 days ago
| Entity Name | St Martin Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407175615 PECOS PAC ID: 4688720782 Enrollment ID: O20101020001032 |
News Archive
In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).
Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.
Antihistamines and nasal steroids offer good short-term options for people with mild allergy, but allergy immunotherapy, better known as "allergy shots," is a preferred method for achieving long term remission of more bothersome allergy symptoms. Allergists mark the 100th anniversary of immunotherapy and present the latest advances at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting in Phoenix, Nov. 11-16.
Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Luris Sanchez, MD 828 Creswell Ln, Opelousas, LA 70570-5882 Ph: (337) 942-8088 | Luris Sanchez, MD 828 Creswell Ln, Opelousas, LA 70570-5882 Ph: (337) 942-8088 |
News Archive
In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).
Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.
Antihistamines and nasal steroids offer good short-term options for people with mild allergy, but allergy immunotherapy, better known as "allergy shots," is a preferred method for achieving long term remission of more bothersome allergy symptoms. Allergists mark the 100th anniversary of immunotherapy and present the latest advances at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting in Phoenix, Nov. 11-16.
Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.
› Verified 3 days ago
Dr. Michael Wayne Basile, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3921 I 49 S Service Rd, Opelousas, LA 70570 Phone: 337-942-5706 Fax: 337-942-2644 | |
Dr. Stacey Wayne Mayeaux, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 519 E Prudhomme St, Opelousas, LA 70570 Phone: 337-678-3755 Fax: 337-678-3757 | |
Dr. Latonya Renae Kelly, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3921 I 49 S Service Rd, Opelousas, LA 70570 Phone: 337-942-5706 Fax: 337-942-2644 | |
Mr. Richard Wayne Harmon, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 827 N Union St, Opelousas, LA 70570 Phone: 337-948-1802 Fax: 337-942-9074 | |
Dr. Adenike Abimbola Tinubu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1270 Attakapas Dr, Suite 404, Opelousas, LA 70570 Phone: 337-678-0918 Fax: 337-678-0927 | |
Dr. Natalie Cecilia Phillips, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3983 I-49 South Service Road, Opelousas General Hospital South Campus, Opelousas, LA 70571 Phone: 337-948-3011 |